By Mill Chart
Last update: Mar 15, 2024
Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is suited for quality investing. Investors should of course do their own research, but we spotted NEUROCRINE BIOSCIENCES INC showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.
ChartMill employs a sophisticated system to assign a Fundamental Rating to every stock in its analysis. This rating, which ranges from 0 to 10, is determined by carefully assessing multiple fundamental indicators and properties.
Overall NBIX gets a fundamental rating of 8 out of 10. We evaluated NBIX against 598 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, NBIX could be worth investigating further for value and growth and quality investing!.
Our latest full fundamental report of NBIX contains the most current fundamental analsysis.
More quality stocks can be found in our Caviar Cruise screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (4/25/2024, 8:34:37 AM)
138.51
-0.46 (-0.33%)
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...
DexCom, Blackstone and Royal Caribbean head this list of five stocks.
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.